Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANCEF vs ANCEF IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Respiratory tract infections,Urinary tract infections,Skin and skin structure infections,Biliary tract infections,Bone and joint infections,Genital infections,Septicemia,Endocarditis,Perioperative prophylaxis
Perioperative prophylaxis,Urinary tract infections,Respiratory tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Off-label: Intra-amniotic infection (chorioamnionitis)
1-2 g IV/IM every 8 hours; maximum 6 g/day.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (Cr Cl <10 m L/min); anephric patients up to 40 hours.
Not significantly metabolized; primarily excreted unchanged by renal tubular secretion.
Cefazolin undergoes minimal hepatic metabolism; primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
80-85% bound to serum albumin.
80-86% primarily to albumin.
0.14-0.17 L/kg; primarily extracellular fluid.
0.12-0.14 L/kg (8-14 L in adults); indicates limited extravascular distribution (primarily extracellular fluid).
IM: ~100% (well absorbed); IV: 100%.
IM: 100% (complete absorption); not administered orally.
Cr Cl >55 m L/min: 1-2 g every 8 h. Cr Cl 35-54: 1-2 g every 8-12 h. Cr Cl 11-34: 1-2 g every 12 h. Cr Cl <10: 1-2 g every 24-48 h. Hemodialysis: 1-2 g after dialysis.
Cr Cl >55 m L/min: 1-2 g q8h; Cr Cl 35-54: 1-2 g q8h (caution); Cr Cl 11-34: 1-2 g q12h; Cr Cl <10: 1-2 g q24h (or 500 mg q12h).
No adjustment required for hepatic impairment.
No dose adjustment required for hepatic impairment. Child-Pugh classification does not alter dosing.
Infants and children 1 month and older: 25-50 mg/kg/day IV/IM divided every 8 h; severe infections: 100 mg/kg/day divided every 6-8 h. Maximum 6 g/day.
Infants and children: 50-100 mg/kg/day IV/IM divided q8h. Severe infections: 100 mg/kg/day, max 6 g/day.
No specific adjustment; use renal function-based dosing as per renal_adjustment.
Dose based on renal function. Use lower end of dosing range due to age-related creatinine clearance decline. Monitor renal function.
No FDA boxed warnings.
No FDA black box warning.
Hypersensitivity reactions, including anaphylaxis, especially in patients with penicillin allergy,Clostridium difficile-associated diarrhea,Renal impairment: dose adjustment required,Prolonged use may result in superinfection,Seizures at high doses in renal impairment
Hypersensitivity reactions including anaphylaxis,Pseudomembranous colitis due to Clostridium difficile,Bleeding risk due to hypoprothrombinemia (rare),Seizures with high doses in renal impairment,Superinfection with prolonged use,Drug interactions with nephrotoxic agents (e.g., aminoglycosides)
Hypersensitivity to cefazolin or other cephalosporins,History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to penicillins
Known hypersensitivity to cefazolin or other cephalosporins,Severe allergic reaction to penicillins (cross-sensitivity)
No significant food interactions. Cefazolin may be administered with or without food. However, alcohol should be avoided due to potential disulfiram-like reaction (cephalosporin side chain effect).
Alcohol may cause disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to interference with acetaldehyde metabolism; avoid alcohol during therapy and for 48 hours after last dose. No other significant food interactions.
No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and third trimesters: no known fetal harm.
Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly needed; second and third trimester use considered safe when indicated.
Excreted in breast milk in low concentrations (M/P ratio unknown, likely low). Considered compatible with breastfeeding due to poor oral bioavailability in infants.
Cefazolin is excreted into human breast milk in low concentrations (M/P ratio approximately 0.02-0.16). Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal disturbances and sensitization.
No dosage adjustment recommended for pregnancy. Increased clearance in pregnancy may necessitate higher doses in severe infections, but standard dosing is typically effective.
No specific dose adjustment recommended in pregnancy. Physiologic increases in plasma volume and renal clearance may theoretically reduce cefazolin concentrations, but standard dosing regimens are considered adequate for prophylaxis and treatment.
Cefazolin (Ancef) is a first-generation cephalosporin with excellent gram-positive coverage, often used for surgical prophylaxis. It has poor CSF penetration, so it is not suitable for meningitis. Cross-allergenicity with penicillins occurs in approximately 10% of patients. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
First-generation cephalosporin; administer IV/IM; adjust dose in renal impairment (Cr Cl <55 m L/min); monitor for hypersensitivity (cross-reactivity in 10% of penicillin-allergic patients); use for surgical prophylaxis (administer within 60 minutes before incision); drug of choice for MSSA infections; tissue penetration good, but CNS penetration limited unless meninges inflamed.
Take exactly as prescribed, even if you feel better.,Complete the full course to prevent resistance.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,May cause diarrhea; contact your doctor if severe or persistent.,Avoid alcohol during treatment and for 48 hours after last dose (disulfiram-like reaction possible but rare).
Take exactly as prescribed; complete full course even if feeling better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling) immediately.,Avoid alcohol during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction.,Inform healthcare provider if you have kidney disease, history of colitis, or are pregnant/breastfeeding.,Diarrhea may occur; report if severe, watery, or bloody (possible C. diff infection).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANCEF vs ANCEF IN PLASTIC CONTAINER, answered by our medical review team.
ANCEF is a Cephalosporin Antibiotic that works by First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.. ANCEF IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANCEF and ANCEF IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANCEF is: 1-2 g IV/IM every 8 hours; maximum 6 g/day.. The standard adult dose of ANCEF IN PLASTIC CONTAINER is: 1-2 g IV/IM every 8 hours. Maximum 12 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANCEF and ANCEF IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANCEF is classified as Category C. No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and th. ANCEF IN PLASTIC CONTAINER is classified as Category C. Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.